When was Avicenna founded?

Avicenna was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Avicenna located?

Avicenna is headquartered in Durham, United States.

How many employees does Avicenna have?

As of Apr 30, 2026, the latest employee count at Avicenna is 12.

Is Avicenna a funded company?

Avicenna is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Jul 01, 2024.

When was the latest funding round of Avicenna?

Avicenna's latest funding was a $***** Conventional Debt round on Jul 01, 2024, with participation from 0 investor. Its primary sector is Life Sciences Tech. In United States, the Life Sciences Tech sector has seen $2.55B in funding in 2026 to date.

Where does Avicenna rank among its competitors?

Avicenna ranks 93rd amongst 162 active competitors, of which 67 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was NewLimit, which secured $435M in Jun, 2026.

Who are the top competitors of Avicenna?

Avicenna's top competitors include Evotec, DNAnexus and Insitro. Among them, NewLimit secured the most recent funding round in June, 2026.

Avicenna - 2026 Company Profile, Team, Funding & Competitors

Avicenna is a funded company based in Durham (United States), founded in 2020 by Thomas Kaiser and Pieter Burger. It operates as a Provider of drug development solutions. Avicenna has raised an undisclosed amount in funding. The company has 162 active competitors, including 67 funded and 9 that have exited. Its top competitors include companies like Evotec, DNAnexus and Insitro.

Company Details

Provider of drug development solutions. It uses machine learning enhanced medicinal chemistry to accelerate the lead to candidate optimization process for small molecule drug development. It provides solutions to predict quantitative structure activity relationships and other properties of drug candidates.

Website: www.avicenna-bio.com/
Email ID: *****@avicenna-bio.com

Key Metrics

Founded Year

2020

Location

Durham, United States

Stage

Funding Raised

Latest Funding Round

Conventional Debt, Jul 01, 2024, $*****

Ranked

93^rd among 162 active competitors

Employee Count

12 as on Apr 30, 2026

Similar Companies

Evotec & 186 more

View Avicenna's full profile

Avicenna has raised funding over 1 round.

Here is the list of recent funding rounds of Avicenna:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2024	3253375	Conventional Debt	1073328	2532672	6661031	1047836

Access funding benchmarks and valuations. Sign up today!

View details of Avicenna's funding rounds and investors

The founders of Avicenna are Thomas Kaiser and Pieter Burger. Chris Meldrum is the CEO of Avicenna.

Here are the details of Avicenna's key team members:

Thomas Kaiser: Former Co-Founder of Avicenna.
Pieter Burger: Co-Founder of Avicenna.
Contact Info: 1 email address

View details of Avicenna's Founder profiles and Board Members

Avicenna's employee count trend

Avicenna has 12 employees as of Apr 26. Here is Avicenna's employee count trend over the years:

Uncover Avicenna's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Avicenna include Evotec, DNAnexus and Insitro. Here is the list of Top 10 competitors of Avicenna, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Evotec 1993, Hamburg (Germany), Public	AI-driven life science company accelerating drug discovery and development	$25.1M	Mubadala, Omega Funds & 22 others	76/100
2nd	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	71/100
3rd	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Google Ventures & 18 others	70/100
4th	Immunai Technologies 2018, United States, Series B	Developer of next-generation of immunomodulatory therapeutics	$295M	TLV Partners, Catalio Capital Management ... & 14 others	66/100
5th	Asimov 2017, Boston (United States), Series B	Provider of integrated suite for advanced genetic design and manufacturing	$234M	Andreessen Horowitz, CPP Investments & 11 others	65/100
6th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	64/100
7th	Kinomica 2017, Macclesfield (United Kingdom), Series A	Provider of a bioinformatics platform for the development of precision medicine	$5.16M	BGF, BioCity & 15 others	64/100
8th	Relation 2019, London (United Kingdom), Seed	AI-based drug development tools for researchers	$116M	DCVC, Magnetic Ventures & 9 others	64/100
9th	NewLimit 2022, San Francisco (United States), Series C	Developer of epigenetic reprogramming medicines for aging-related diseases and healthspan extension	$682M	Founders Fund, Lilly & 21 others	63/100
10th	Somite 2023, Boston (United States), Series A	AI-driven platform to produce human tissue for cell-based therapies	$60M	Khosla Ventures, Astellas Venture Management ... & 13 others	63/100
93rd	Avicenna 2020, Durham (United States), Funding Raised	Provider of drug development solutions	-	-	27/100